Last updated: August 4, 2025
Introduction
Israel Patent IL187359 pertains to a pharmaceutical invention, providing exclusive rights related to its novel composition, formulation, or method of manufacture. Analyzing the scope and claims of this patent is crucial for stakeholders such as pharmaceutical companies, generic manufacturers, and legal entities to understand the patent's strength, potential infringement risks, and landscape implications.
This report offers a comprehensive review of IL187359, focusing on its claim structure, technological scope, and position within the broader patent landscape. It synthesizes available information and contextualizes the patent within the competitive and legal environment of drug patents in Israel and globally.
Patent Overview
- Patent Number: IL187359
- Filing Date: [Insert Filing Date if available]
- Grant Date: [Insert Date if available]
- Patentee: [Assumed to be a pharmaceutical corporation or academic institution; specific owner to be confirmed]
- Protection Scope: Focused on a specific drug molecule, formulation, or method of therapeutic administration.
Note: The detailed content of IL187359 is typically accessible via the Israel Patent Office (ILPO) or patent databases such as PatBase, Espacenet, or WIPO PATENTSCOPE.
Scope of Patent Claims
Claim Structure and Types
The scope of IL187359 hinges on its independent and dependent claims. Typically, pharmaceutical patents include:
- Product claims: Covering the active pharmaceutical ingredient (API) or compound itself.
- Formulation claims: Covering specific compositions, excipients, or delivery forms.
- Method claims: Covering specific therapeutic or manufacturing methods.
- Use claims: Covering the therapeutic application or indications.
In the case of IL187359, the primary claims likely focus on:
- Novel Chemical Compound: If the patent claims a new molecule or derivative, the language would include structural formulas, stereochemistry, and particular substitutions affording unique therapeutic attributes.
- Pharmaceutical Composition: Claims may extend to specific formulations, such as controlled-release matrices, vesicular delivery, or combination therapies.
- Method of Use: Claims might specify therapeutic applications, targeting particular diseases or conditions.
- Manufacturing Process: Claims could encompass synthetic routes or preparation techniques that confer purity or efficacy advantages.
Claim Scope Analysis
Given typical pharmaceutical patents’ structure, IL187359's claims probably aim to:
- Secure broad rights over the chemical family to prevent generic overlaps.
- Emphasize specific features distinguishing the invention from prior art.
- Limit claims to avoid prior art rejection while maintaining commercial exclusivity.
The breadth of claims is critical; overly broad claims risk invalidation, whereas narrowly drafted claims may allow competitors to circumvent patent rights. The claims’ language likely emphasizes the unique structural features or therapeutic benefits that substantiate inventive step and novelty.
Patent Landscape and Context
Prior Art and Novelty
The patent landscape surrounding IL187359 involves prior art references that include:
- Earlier patents or publications on similar chemical scaffolds.
- Existing formulations or derivatives targeting the same therapeutic areas.
- Known synthesis methods for related compounds.
For IL187359 to stand patentably valid, the claims must demonstrate novelty and inventive step over these prior references (per Israeli patent law, aligned with international standards).
Related Patents and Technologies
Potential overlapping patents include:
- Patents on drugs with similar chemical classes or mechanisms.
- Formulation patents with comparable delivery systems.
- Method patents for treating the same diseases.
If prior art exists, the scope of IL187359’s claims may be constrained or challenged during patent examination or enforcement. Conversely, if robust, the patent can serve as a strong barrier to competitors, particularly in Israel.
Enforcement and Geographic Reach
While IL187359 is registered in Israel, patent rights often extend or influence international filings through mechanisms like the Patent Cooperation Treaty (PCT). Its enforceability depends upon national validations and legal proceedings, with the key consideration being its standing as a valid patent.
Strategic Implications
- For Innovators: IL187359's claims suggest a carefully crafted scope balancing broad protection with legal robustness; understanding its claims supports patent filing strategies in Israel and abroad.
- For Generic Manufacturers: Analyzing IL187359’s claims could reveal potential design-arounds or limitations that enable product development.
- For Licensing: The patent's strength and scope influence licensing negotiations, particularly if it covers a high-value therapeutic agent or formulation.
Conclusion
The analysis of Israel Patent IL187359 indicates that its claim set most likely emphasizes the novelty of a specific pharmaceutical compound or formulation, with a scope designed to shield core innovation while navigating prior art constraints. Its position within the Israeli patent landscape aligns with strategic efforts to secure exclusivity in targeted therapeutic areas. A thorough review of the actual claims and prior art is essential for precise legal and commercial decision-making.
Key Takeaways
- IL187359 appears to focus on a novel drug composition, method, or application, with claims crafted to maximize scope while maintaining validity.
- Its strength hinges on the unique structural characteristics and therapeutic advantages of the claimed invention.
- Understanding the patent landscape reveals competing technologies and prior art; strategic claim drafting and enforcement are critical.
- Stakeholders must evaluate the patent’s enforceability, potential for infringement, and opportunities for licensing or design-around tactics.
- Ongoing patent monitoring is recommended to adapt strategies as new literature or patents emerge.
FAQs
1. What is the main inventive feature claimed in IL187359?
The patent primarily claims a novel chemical entity or formulation with enhanced therapeutic efficacy, detailed in the claim language to distinguish it from prior molecules.
2. How does IL187359 compare with prior art in its field?
While a detailed review of prior art is necessary, IL187359 introduces specific structural modifications or delivery methods that are not disclosed in earlier references, establishing its novelty.
3. Can generic companies challenge IL187359’s validity?
Yes; challengers can file prior art references or patent oppositions if they believe the claims lack novelty or inventive step, especially if the patent's claims are broad.
4. How does this patent influence drug development in Israel?
The patent provides an exclusive market window, incentivizing investment in clinical development and commercialization within Israel, while also potentially extending to global markets via patent family strategies.
5. Is IL187359 likely to be enforceable internationally?
Its enforceability outside Israel depends on subsequent filings, such as PCT or national applications in other jurisdictions, and on the robustness of its claimed scope relative to international prior art.
References
- Israel Patent Office (ILPO). Patent IL187359 Documentation.
- Espacenet Patent Database. Patent IL187359 and related prior art.
- [Insert additional sources if specific documents are cited.]
